Orthofix Medical Inc. (NASDAQ:OFIX) Receives $18.00 Consensus Target Price from Analysts

Orthofix Medical Inc. (NASDAQ:OFIX) has been given a consensus recommendation of “Hold” by the five brokerages that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $18.00.

Several equities analysts have recently weighed in on the company. Roth Capital raised Orthofix Medical from a “neutral” rating to a “buy” rating in a report on Wednesday, May 8th. StockNews.com raised Orthofix Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, May 8th. JMP Securities restated a “market perform” rating on shares of Orthofix Medical in a research note on Monday, April 22nd. Finally, Roth Mkm upgraded shares of Orthofix Medical from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $15.00 to $20.00 in a research note on Wednesday, May 8th.

Orthofix Medical Price Performance

Shares of NASDAQ:OFIX opened at $13.29 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.19 and a current ratio of 2.65. The firm has a market cap of $498.76 million, a price-to-earnings ratio of -3.93 and a beta of 1.05. The business has a 50-day simple moving average of $13.72 and a two-hundred day simple moving average of $13.75. Orthofix Medical has a fifty-two week low of $9.57 and a fifty-two week high of $21.60.

Orthofix Medical (NASDAQ:OFIX) last announced its quarterly earnings results on Tuesday, May 7th. The medical device company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.41). The company had revenue of $188.61 million during the quarter, compared to the consensus estimate of $183.40 million. Orthofix Medical had a negative return on equity of 14.24% and a negative net margin of 16.64%. On average, analysts expect that Orthofix Medical will post -1.88 earnings per share for the current year.

Institutional Trading of Orthofix Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Engine Capital Management LP purchased a new stake in Orthofix Medical in the 4th quarter worth approximately $40,916,000. Jump Financial LLC bought a new position in shares of Orthofix Medical in the fourth quarter worth approximately $1,445,000. Boone Capital Management LLC purchased a new stake in shares of Orthofix Medical in the fourth quarter worth $6,740,000. Charles Schwab Investment Management Inc. raised its position in shares of Orthofix Medical by 7.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 461,885 shares of the medical device company’s stock valued at $6,226,000 after purchasing an additional 32,400 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Orthofix Medical by 30.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,516 shares of the medical device company’s stock valued at $101,000 after buying an additional 1,752 shares in the last quarter. Hedge funds and other institutional investors own 89.76% of the company’s stock.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.